HESTER BIOSCIENCES
|
HESTER BIOSCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 65.40 | 32.31 | 22.20 | 31.30 | 46.22 |
| CEPS(Rs) | 89.77 | 53.64 | 45.07 | 57.28 | 65.90 |
| DPS(Rs) | 11.00 | 7.00 | 6.00 | 8.00 | 10.00 |
| Book NAV/Share(Rs) | 423.46 | 369.41 | 343.00 | 328.82 | 305.61 |
| Tax Rate(%) | 24.20 | 27.15 | 33.76 | 30.18 | 26.20 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 24.62 | 19.61 | 17.44 | 18.81 | 25.32 |
| EBIT Margin(%) | 26.07 | 16.79 | 16.97 | 18.46 | 24.30 |
| Pre Tax Margin(%) | 22.79 | 12.71 | 10.48 | 14.98 | 22.58 |
| PAT Margin (%) | 17.27 | 9.26 | 6.94 | 10.46 | 16.67 |
| Cash Profit Margin (%) | 22.95 | 14.66 | 12.58 | 18.18 | 23.67 |
| Performance Ratios | |||||
| ROA(%) | 8.64 | 4.38 | 3.18 | 4.55 | 8.11 |
| ROE(%) | 17.05 | 9.51 | 7.41 | 10.39 | 16.17 |
| ROCE(%) | 16.21 | 9.93 | 9.59 | 9.60 | 14.12 |
| Asset Turnover(x) | 0.50 | 0.47 | 0.46 | 0.44 | 0.49 |
| Sales/Fixed Asset(x) | 0.68 | 0.81 | 0.79 | 0.73 | 0.82 |
| Working Capital/Sales(x) | 5.93 | 4.45 | 2.79 | 3.40 | 2.42 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.47 | 1.24 | 1.26 | 1.37 | 1.22 |
| Receivable days | 92.43 | 89.02 | 94.77 | 91.87 | 80.50 |
| Inventory Days | 78.37 | 85.58 | 96.04 | 109.08 | 106.00 |
| Payable days | 120.46 | 114.21 | 106.28 | 113.04 | 129.73 |
| Valuation Parameters | |||||
| PER(x) | 19.31 | 38.81 | 62.57 | 48.58 | 58.75 |
| PCE(x) | 14.07 | 23.38 | 30.83 | 26.54 | 41.20 |
| Price/Book(x) | 2.98 | 3.39 | 4.05 | 4.62 | 8.88 |
| Yield(%) | 0.87 | 0.56 | 0.43 | 0.53 | 0.37 |
| EV/Net Sales(x) | 3.78 | 4.07 | 4.62 | 5.81 | 10.67 |
| EV/Core EBITDA(x) | 13.04 | 19.50 | 21.86 | 23.52 | 34.01 |
| EV/EBIT(x) | 14.47 | 24.24 | 27.17 | 31.26 | 43.55 |
| EV/CE(x) | 2.29 | 2.43 | 2.65 | 2.82 | 4.46 |
| M Cap / Sales | 3.23 | 3.43 | 3.88 | 4.86 | 9.83 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.91 | 2.15 | 14.45 | 13.23 | 9.65 |
| Core EBITDA Growth(%) | 48.27 | 1.06 | -2.23 | -10.80 | 0.52 |
| EBIT Growth(%) | 65.99 | 1.06 | 4.56 | -14.06 | 1.51 |
| PAT Growth(%) | 99.42 | 36.19 | -24.50 | -29.00 | 13.79 |
| EPS Growth(%) | 102.41 | 45.52 | -29.06 | -32.28 | 14.20 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.52 | 0.66 | 0.82 | 0.96 | 0.86 |
| Current Ratio(x) | 1.37 | 1.56 | 2.03 | 1.53 | 2.01 |
| Quick Ratio(x) | 0.89 | 1.00 | 1.32 | 0.96 | 1.23 |
| Interest Cover(x) | 7.94 | 4.12 | 2.62 | 5.31 | 14.16 |
| Total Debt/Mcap(x) | 0.18 | 0.19 | 0.20 | 0.21 | 0.10 |
Compare Financial Ratios of peers of HESTER BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| HESTER BIOSCIENCES | ₹1,765.3 Cr | 0.4% | 12.9% | 10.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹440,794.0 Cr | 1.7% | -2.3% | 8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹178,956.0 Cr | 2% | -2.2% | 1.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹149,820.0 Cr | -1.8% | -0.1% | 36.7% | Stock Analytics | |
| CIPLA | ₹109,370.0 Cr | -2% | -3.3% | -9.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,133.0 Cr | -0.6% | -3.8% | -6.9% | Stock Analytics | |
HESTER BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| HESTER BIOSCIENCES | 0.4% |
12.9% |
10.5% |
| SENSEX | 1.7% |
2.1% |
-6% |
You may also like the below Video Courses
